



**Arix Bioscience plc**

## **Completion of sale of VelosBio**

**LONDON, 18 December 2020:** Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the completion of the [previously announced](#) sale of its portfolio company VelosBio Inc. (“VelosBio”), to Merck & Co., Inc., Kenilworth NJ., USA, for final all cash consideration of \$2.75 billion.

The trade sale of VelosBio generates gross proceeds of \$187.0 million (£138.5 million)<sup>1</sup> to Arix, representing a 12.5x return on its original investment of \$15.0 million (£11.8 million) and an internal rate of return (IRR) of 328%.

The tax treatment of this transaction will be detailed within Arix’s 2020 Annual Report and Accounts, to be published in March 2021.

[ENDS]

### **Enquiries**

For more information on Arix, please contact:

#### **Arix Bioscience plc**

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

[charlotte@arixbioscience.com](mailto:charlotte@arixbioscience.com)

#### **Optimum Strategic Communications**

Supriya Mathur, Shabnam Bashir, Manel Mateus

+44 (0)20 3922 1906

[optimum.arix@optimumcomms.com](mailto:optimum.arix@optimumcomms.com)

### **About Arix Bioscience plc**

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

For more information please visit: [www.arixbioscience.com](http://www.arixbioscience.com)

---

<sup>1</sup> At GBP/USD FX rate of 1.3500